MedPAC > Our Work > Drugs, Devices, and Tests > MedPAC comment on CMS’s proposed rule on the remedy for the 340B-acquired drug payment policy for calendar years 2018-2022
MedPAC comment on CMS’s proposed rule on the remedy for the 340B-acquired drug payment policy for calendar years 2018-2022